Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02853097 · ClinicalTrials.gov registry record
Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients
A clinical trial, sponsored by University of Southern California.
- Terminated
- Registry status
- 7
- Enrollment target
NCT02853097: Clinical Trial study, sponsored by University of Southern California.
NCT02853097 is a clinical trial that was terminated before completion, run by University of Southern California. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02853097 was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- 7 participants
- Enrollment target
Study Summary
This research trial studies cell-free deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in blood from patients with prostate cancer that does not respond to hormone therapy and has spread to other places in the body. Studying samples of blood from patients with prostate cancer may help doctors to learn more about the changes that occur in tumor cells over time and how they become resistant to anti-cancer drugs.
Primary Outcome
Each of the 4 longitudinal cohorts will be analyzed separately (at least initially). Kaplan-Meier-like curves (likely adjusted for interval censoring) will be used to display the development of AR-V7 positivity. To complement the analysis of Cohort A, an exact logistic regression analysis will be used with the data from Cohort X with AR-V7 splice variant positivity as the dependent variable and time since start of ADT as the independent variable. Logistic regression will be used to assess the as
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Cytology Specimen Collection Procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-06-14 |
| Est. Completion | 2020-09-27 |
Why NCT02853097 stopped before completion
NCT02853097 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 7 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02853097 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02853097 about?
NCT02853097 is a clinical study titled "Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients". This research trial studies cell-free deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in blood from patients with prostate cancer that does not respond to hormone therapy and has spread to other places in the body. Studying samples of blood from patients with prostate cancer may help doctors ...
What is the current status of trial NCT02853097?
This trial is currently terminated. The enrollment target is 7 participants. The study started on 2016-06-14. Estimated completion is 2020-09-27.
What interventions are being tested in trial NCT02853097?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Cytology Specimen Collection Procedure (OTHER).
Who is sponsoring clinical trial NCT02853097?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI